New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy

Nurse, 1975, Genetic control of cell size at cell division in yeast, Nature, 256, 547, 10.1038/256547a0 Hartwell, 1970, Genetic control of the cell-division cycle in yeast. I. Detection of mutants, Proc. Natl. Acad. Sci. U. S. A., 66, 352, 10.1073/pnas.66.2.352 Lee, 1987, Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2, Nature, 327, 31, 10.1038/327031a0 Xiong, 1991, Human D-type cyclin, Cell, 65, 691, 10.1016/0092-8674(91)90100-D Matsushime, 1991, Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle, Cell, 65, 701, 10.1016/0092-8674(91)90101-4 Lew, 1991, Isolation of three novel human cyclins by rescue of G1 cyclin (cln) function in yeast, Cell, 66, 1197, 10.1016/0092-8674(91)90042-W Matsushime, 1992, Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins, Cell, 71, 323, 10.1016/0092-8674(92)90360-O Morrison, 2012, MAP kinase pathways, Cold Spring Harb. Perspect. Biol., 4, 10.1101/cshperspect.a011254 Duronio, 2013, Signaling pathways that control cell proliferation, Cold Spring Harb. Perspect. Biol., 5, 10.1101/cshperspect.a008904 Blagosklonny, 2003, Cell senescence and hypermitogenic arrest, EMBO Rep., 4, 358, 10.1038/sj.embor.embor806 Wade Harper, 1993, The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases, Cell, 75, 805, 10.1016/0092-8674(93)90499-G Gu, 1993, Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit, Nature, 366, 707, 10.1038/366707a0 Polyak, 1994, p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest, Genes Dev., 8, 9, 10.1101/gad.8.1.9 Polyak, 1994, Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals, Cell, 78, 59, 10.1016/0092-8674(94)90572-X Matsuoka, 1995, p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene, Genes Dev., 9, 650, 10.1101/gad.9.6.650 Lee, 1995, Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution, Genes Dev., 9, 639, 10.1101/gad.9.6.639 Hannon, 1994, p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest, Nature, 371, 257, 10.1038/371257a0 Serrano, 1993, A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4, Nature, 366, 704, 10.1038/366704a0 Guan, 1994, Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function, Genes Dev., 8, 2939, 10.1101/gad.8.24.2939 Hirai, 1995, Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6, Mol. Cell Biol., 15, 2672, 10.1128/MCB.15.5.2672 Chan, 1995, Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4, Mol. Cell Biol., 15, 2682, 10.1128/MCB.15.5.2682 Sherr, 1999, CDK inhibitors: positive and negative regulators of G1-phase progression, Genes Dev., 13, 1501, 10.1101/gad.13.12.1501 Tafforeau, 2013, The complexity of human ribosome biogenesis revealed by systematic nucleolar screening of Pre-rRNA processing factors, Mol. Cell, 51, 539, 10.1016/j.molcel.2013.08.011 Ruggero, 2003, Does the ribosome translate cancer?, Nat. Rev. Cancer, 3, 179, 10.1038/nrc1015 White, 2005, RNA polymerases I and III, growth control and cancer, Nat. Rev. Mol. Cell Biol., 6, 69, 10.1038/nrm1551 Mullineux, 2012, Mapping the cleavage sites on mammalian pre-rRNAs: where do we stand?, Biochimie, 94, 1521, 10.1016/j.biochi.2012.02.001 White, 2008, RNA polymerases I and III, non-coding RNAs and cancer, Trends Genet., 24, 622, 10.1016/j.tig.2008.10.003 Klinge, 2019, Ribosome assembly coming into focus, Nat. Rev. Mol. Cell Biol., 20, 116, 10.1038/s41580-018-0078-y Slimane, 2020, Ribosome biogenesis alterations in colorectal cancer, Cells, 9, 236 Ban, 2014, A new system for naming ribosomal proteins, Curr. Opin. Struct. Biol., 24, 165, 10.1016/j.sbi.2014.01.002 Zhou, 2015, Ribosomal proteins: functions beyond the ribosome, J. Mol. Cell Biol., 7, 92, 10.1093/jmcb/mjv014 Lessard, 2019, Ribosomal proteins control tumor suppressor pathways in response to nucleolar stress, Bioessays, 41, 10.1002/bies.201800183 Ebright, 2020, Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis, Science, 367, 1468, 10.1126/science.aay0939 Orsolic, 2020, Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint, Oncogene, 39, 3443, 10.1038/s41388-020-1231-6 Girardi, 2018, The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling, Leukemia, 32, 809, 10.1038/leu.2017.225 Kampen, 2018, The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL, Leukemia, 33, 319, 10.1038/s41375-018-0176-z Ajore, 2017, Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations, EMBO Mol. Med., 9, 498, 10.15252/emmm.201606660 Pfister, 2019, Emerging role of the nucleolar stress response in autophagy, Front. Cell. Neurosci., 13, 156, 10.3389/fncel.2019.00156 Pagliara, 2016, 5-FU targets rpL3 to induce mitochondrial apoptosis via cystathionine-beta-synthase in colon cancer cells lacking p53, Oncotarget, 7, 50333, 10.18632/oncotarget.10385 Pecoraro, 2019, Ribosomal protein uL3 targets E2F1 and Cyclin D1 in cancer cell response to nucleolar stress, Sci. Rep., 9, 10.1038/s41598-019-51723-7 Pecoraro, 2020, uL3 mediated nucleolar stress pathway as a new mechanism of action of antiproliferative G-quadruplex TBA derivatives in colon cancer cells, Biomolecules, 10, 583, 10.3390/biom10040583 Han, 2017, New role of human ribosomal protein S3: Regulation of cell cycle via phosphorylation by cyclin-dependent kinase 2, Oncol. Lett., 13, 3681, 10.3892/ol.2017.5906 Liao, 2014, Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex, Oncogene, 33, 4916, 10.1038/onc.2013.430 Zhou, 2013, Ribosomal protein S14 negatively regulates c-Myc activity, J. Biol. Chem., 288, 21793, 10.1074/jbc.M112.445122 Wan, 2007, Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation, Cell, 131, 927, 10.1016/j.cell.2007.10.009 Wan, 2011, IKKbeta phosphorylation regulates RPS3 nuclear translocation and NF-kappaB function during infection with Escherichia coli strain O157:H7, Nat. Immunol., 12, 335, 10.1038/ni.2007 Wang, 2013, Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways, PLoS ONE, 8 Sawyer, 2020, Exploiting codon usage identifies intensity-specific modifiers of Ras/MAPK signaling in vivo, PLoS Genet., 16, 10.1371/journal.pgen.1009228 Shi, 2017, Heterogeneous ribosomes preferentially translate distinct subpools of mRNAs genome-wide, Mol. Cell, 67, 71, 10.1016/j.molcel.2017.05.021 Lessard, 2018, Senescence-associated ribosome biogenesis defects contributes to cell cycle arrest through the Rb pathway, Nat. Cell Biol., 20, 789, 10.1038/s41556-018-0127-y Del Toro, 2019, Ribosomal protein RPL22/eL22 regulates the cell cycle by acting as an inhibitor of the CDK4-cyclin D complex, Cell Cycle, 18, 759, 10.1080/15384101.2019.1593708 Belyi, 2010, The origins and evolution of the p53 family of genes, Cold Spring Harb. Perspect. Biol., 2, 10.1101/cshperspect.a001198 Barik, 2010, A model of yeast cell-cycle regulation based on multisite phosphorylation, Mol. Syst. Biol., 6, 405, 10.1038/msb.2010.55 Costanzo, 2010, The genetic landscape of a cell, Science, 327, 425, 10.1126/science.1180823 Costanzo, 2016, A global genetic interaction network maps a wiring diagram of cellular function, Science, 353, 10.1126/science.aaf1420 Srivas, 2016, A network of conserved synthetic lethal interactions for exploration of precision cancer therapy, Mol. Cell, 63, 514, 10.1016/j.molcel.2016.06.022 Kuzmin, 2018, Systematic analysis of complex genetic interactions, Science, 360, 10.1126/science.aao1729 Huang, 2007, Pho85, a multifunctional cyclin-dependent protein kinase in budding yeast, Mol. Microbiol., 66, 303, 10.1111/j.1365-2958.2007.05914.x Fasolo, 2011, Diverse protein kinase interactions identified by protein microarrays reveal novel connections between cellular processes, Genes Dev., 25, 767, 10.1101/gad.1998811 Ptacek, 2005, Global analysis of protein phosphorylation in yeast, Nature, 438, 679, 10.1038/nature04187 Rother, 2007, The RNA polymerase II CTD kinase Ctk1 functions in translation elongation, Genes Dev., 21, 1409, 10.1101/gad.428407 Krogan, 2006, Global landscape of protein complexes in the yeast Saccharomyces cerevisiae, Nature, 440, 637, 10.1038/nature04670 Gavin, 2006, Proteome survey reveals modularity of the yeast cell machinery, Nature, 440, 631, 10.1038/nature04532 Yahya, 2014, A Whi7-anchored loop controls the G1 Cdk-cyclin complex at start, Mol. Cell, 53, 115, 10.1016/j.molcel.2013.11.015 So, 2015, Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy, Sci. Signal, 8, 10.1126/scisignal.2005700 Varjosalo, 2013, Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS, Nat. Methods, 10, 307, 10.1038/nmeth.2400 Neganova, 2011, An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells, Stem Cells, 29, 651, 10.1002/stem.620 Yang, 2015, Systematic determination of human cyclin dependent kinase (CDK)-9 interactome identifies novel functions in RNA splicing mediated by the DEAD Box (DDX)-5/17 RNA helicases, Mol. Cell. Proteomics, 14, 2701, 10.1074/mcp.M115.049221 Moorthamer, 1999, Identification of ribosomal protein L34 as a novel Cdk5 inhibitor, Biochem. Biophys. Res. Commun., 255, 631, 10.1006/bbrc.1999.0145 Elgar, 2008, Tuning in to the signals: noncoding sequence conservation in vertebrate genomes, Trends Genet., 24, 344, 10.1016/j.tig.2008.04.005 Ko, 2013, Epigenomics: the science of no-longer-junk DNA. Why study it in chronic kidney disease?, Semin. Nephrol., 33, 354, 10.1016/j.semnephrol.2013.05.007 Richard Boland, 2017, Non-coding RNA: it's not junk, Dig. Dis. Sci., 62, 1107, 10.1007/s10620-017-4506-1 He, 2017, Senescence in health and disease, Cell, 169, 1000, 10.1016/j.cell.2017.05.015 Finn, 2009, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro, Breast Cancer Res., 11, R77, 10.1186/bcr2419 Rocca, 2014, Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer, Expert. Opin. Pharmacother., 15, 407, 10.1517/14656566.2014.870555 Tate, 2014, Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts, Clin. Cancer Res., 20, 3763, 10.1158/1078-0432.CCR-13-2846 Gelbert, 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine, Investig. New Drugs, 32, 825, 10.1007/s10637-014-0120-7 Lu, 2015, Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer, J. Hematol. Oncol., 8, 98, 10.1186/s13045-015-0194-5 Hortobagyi, 2016, Ribociclib as first-line therapy for HR-positive, advanced breast cancer, N. Engl. J. Med., 375, 1738, 10.1056/NEJMoa1609709 Saleh, 2020, CDK4/6 inhibitors in breast cancer - from in vitro models to clinical trials, Acta Oncol., 59, 219, 10.1080/0284186X.2019.1684559 Weeks, 2019, The nucleolus: a central response hub for the stressors that drive cancer progression, Cell. Mol. Life Sci., 76, 4511, 10.1007/s00018-019-03231-0 Russo, 2017, Role of uL3 in multidrug resistance in p53-mutated lung cancer cells, Int. J. Mol. Sci., 18, 547, 10.3390/ijms18030547 Pecoraro, 2020, Role of uL3 in the crosstalk between nucleolar stress and autophagy in colon cancer cells, Int. J. Mol. Sci., 21, 2143, 10.3390/ijms21062143 Pecoraro, 2020, Role of autophagy in cancer cell response to nucleolar and endoplasmic reticulum stress, Int. J. Mol. Sci., 21, 7334, 10.3390/ijms21197334 Mars, 2020, The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability, NAR Cancer, 2, 10.1093/narcan/zcaa032 Bywater, 2012, Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53, Cancer Cell, 22, 51, 10.1016/j.ccr.2012.05.019 Sanij, 2020, CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer, Nat. Commun., 11, 2641, 10.1038/s41467-020-16393-4 Yan, 2020, The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer, Br. J. Cancer, 124, 616, 10.1038/s41416-020-01158-z Saxton, 2017, mTOR signaling in growth, metabolism, and disease, Cell, 168, 960, 10.1016/j.cell.2017.02.004 Li, 2016, CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma, Onco Targets Ther., 9, 5985, 10.2147/OTT.S104513 Shi, 2021, Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma, Biomed. Pharmacother., 133, 10.1016/j.biopha.2020.110906 Nalawansha, 2020, PROTACs: an emerging therapeutic modality in precision medicine, Cell Chem. Biol., 27, 998, 10.1016/j.chembiol.2020.07.020 Rana, 2019, Selective degradation of CDK6 by a palbociclib based PROTAC, Bioorg. Med. Chem. Lett., 29, 1375, 10.1016/j.bmcl.2019.03.035 Gonzalez, 2020, RINGO/Speedy proteins, a family of non-canonical activators of CDK1 and CDK2, Semin. Cell Dev. Biol., 107, 21, 10.1016/j.semcdb.2020.03.010 Al Sorkhy, 2016, Direct interactions with both p27 and Cdk2 regulate Spy1-mediated proliferation in vivo and in vitro, Cell Cycle, 15, 128, 10.1080/15384101.2015.1121327 Frontini, 2012, The CDK subunit CKS2 counteracts CKS1 to control cyclin A/CDK2 activity in maintaining replicative fidelity and neurodevelopment, Dev. Cell, 23, 356, 10.1016/j.devcel.2012.06.018 McGrath, 2013, Cks confers specificity to phosphorylation-dependent CDK signaling pathways, Nat. Struct. Mol. Biol., 20, 1407, 10.1038/nsmb.2707 Khattar, 2013, Cks1: structure, emerging roles and implications in multiple cancers, J. Cancer Ther., 4, 1341, 10.4236/jct.2013.48159 van Zon, 2010, The APC/C recruits cyclin B1-Cdk1-Cks in prometaphase before D box recognition to control mitotic exit, J. Cell Biol., 190, 587, 10.1083/jcb.200912084 Fujimitsu, 2020, PP2A-B56 binds to Apc1 and promotes Cdc20 association with the APC/C ubiquitin ligase in mitosis, EMBO Rep., 21, 10.15252/embr.201948503 Himeda, 2019, The good, the bad, and the unexpected: roles of DUX4 in health and disease, Dev. Cell, 50, 525, 10.1016/j.devcel.2019.08.010 Dib, 2019, DUX4 pathological expression: causes and consequences in cancer, Trends Cancer, 5, 268, 10.1016/j.trecan.2019.03.001 Lim, 2020, DUX4 signalling in the pathogenesis of facioscapulohumeral muscular dystrophy, Int. J. Mol. Sci., 21, 729, 10.3390/ijms21030729 Bosnakovski, 2008, An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies, EMBO J., 27, 2766, 10.1038/emboj.2008.201 Bosnakovski, 2017, The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain, J. Cell Sci., 130, 3685 Bury, 2019, NFE2L3 controls colon cancer cell growth through regulation of DUX4, a CDK1 inhibitor, Cell Rep., 29, 1469, 10.1016/j.celrep.2019.09.087 Santamaria, 2007, Cdk1 is sufficient to drive the mammalian cell cycle, Nature, 448, 811, 10.1038/nature06046 El-Deiry, 1993, WAF1, a potential mediator of p53 tumor suppression, Cell, 75, 817, 10.1016/0092-8674(93)90500-P Loughery, 2013, Switching on p53: an essential role for protein phosphorylation?, Biodiscovery, 8 Haupt, 1997, Mdm2 promotes the rapid degradation of p53, Nature, 387, 296, 10.1038/387296a0 Kubbutat, 1997, Regulation of p53 stability by Mdm2, Nature, 387, 299, 10.1038/387299a0 Takagi, 2005, Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin, Cell, 123, 49, 10.1016/j.cell.2005.07.034 Rashkovan, 2014, Miz-1 regulates translation of Trp53 via ribosomal protein L22 in cells undergoing V(D)J recombination, Proc. Natl. Acad. Sci. U. S. A., 111, E5411, 10.1073/pnas.1412107111 Zhang, 2010, Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26, Nucleic Acids Res., 38, 6544, 10.1093/nar/gkq536 Lohrum, 2003, Regulation of HDM2 activity by the ribosomal protein L11, Cancer Cell, 3, 577, 10.1016/S1535-6108(03)00134-X Dai, 2004, Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5, J. Biol. Chem., 279, 44475, 10.1074/jbc.M403722200 Zheng, 2015, Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation, Genes Dev., 29, 1524, 10.1101/gad.261792.115 Liu, 2016, RP-MDM2-p53 pathway: linking ribosomal biogenesis and tumor surveillance, Trends Cancer, 2, 191, 10.1016/j.trecan.2016.03.002 Bruno, 2017, A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress, Nat. Med., 23, 461, 10.1038/nm.4291 Sun, 2007, 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction, J. Biol. Chem., 282, 8052, 10.1074/jbc.M610621200